Newron Pharmaceuticals Financials
| NWRN Stock | CHF 7.50 0.41 5.78% |
Newron |
Understanding current and past Newron Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Newron Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Newron Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Newron Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Newron Pharmaceuticals SpA. Check Newron Pharmaceuticals' Beneish M Score to see the likelihood of Newron Pharmaceuticals' management manipulating its earnings.
Newron Pharmaceuticals Stock Summary
Newron Pharmaceuticals competes with Santhera Pharmaceuticals, Basilea Pharmaceutica, Evolva Holding, and COSMO Pharmaceuticals. Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company was founded in 1998 and is headquartered in Bresso, Italy. NEWRON PHARMA operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 24 people.| Instrument | Switzerland Stock View All |
| Exchange | SIX Swiss Exchange |
| ISIN | IT0004147952 |
| Business Address | Via Antonio Meucci |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.newron.com |
| Phone | 39 02 610 3461 |
| Currency | CHF - Swiss Franc |
You should never invest in Newron Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Newron Stock, because this is throwing your money away. Analyzing the key information contained in Newron Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Newron Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Newron Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Newron Pharmaceuticals reports annually and quarterly.Newron Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Newron Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Newron Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Newron Pharmaceuticals competition to find correlations between indicators driving Newron Pharmaceuticals's intrinsic value. More Info.Newron Pharmaceuticals SpA is considered to be number one stock in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Newron Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Newron Pharmaceuticals Systematic Risk
Newron Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Newron Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Newron Pharmaceuticals correlated with the market. If Beta is less than 0 Newron Pharmaceuticals generally moves in the opposite direction as compared to the market. If Newron Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Newron Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Newron Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Newron Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Newron Pharmaceuticals November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Newron Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Newron Pharmaceuticals SpA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Newron Pharmaceuticals SpA based on widely used predictive technical indicators. In general, we focus on analyzing Newron Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Newron Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 19.08 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 6.13 |
Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.